FDA grants Priority Review for IMAAVY (nipocalimab‑aahu) in warm autoimmune hemolytic anemia
IMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions
























